Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tolerance to desvenlafaxine in rapid metabolizing depressed patients.

International clinical psychopharmacology - 1 Mar 2011

Parker Gordon B, Brotchie Heather L, Hyett Matthew

Abstract excerpt

The terms 'tolerance' and 'poop out' are commonly applied to describe the progressive loss of effectiveness of a previously effective antidepressant and where the individual may be a rapid metabolizer of those drugs as a consequence of possessing certain polymorphisms of P450 (CYP) liver enzymes, especially CYP2D6 and CYP2C19. As the antidepressant desvenlafaxine is not metabolized by those enzymes, it might be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antidepressive Agents, Second-Generation
Share to Cyclohexanols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 Enzyme System

Share to Depressive Disorder, Major

Share to Drug Tolerance

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 21119521
DOI: 10.1097/YIC.0b013e328341e333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tolerance to desvenlafaxine in rapid metabolizing depressed patients.PMID 21119521Read ↗

Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.Semantic proximity Read ↗

Association between CYP2D6 genotype and vortioxetine exposure and therapeutic failure - a retrospective, cohort studySemantic proximity Read ↗

Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.Semantic proximity Read ↗

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.Semantic proximity Read ↗

[Retrospective assessment of the antidepressants tolerance in the group of patients with diagnosis of depression and different CYP2D6 genotype].Semantic proximity Read ↗

Adverse drug reactions following nonresponse in a depressed patient with CYP2D6 deficiency and low CYP 3A4/5 activity.Semantic proximity Read ↗

Association Between CYP2D6 Metabolizer Status and Vortioxetine Exposure and Treatment Switching: A Retrospective, Naturalistic Cohort Study Using Therapeutic Drug Monitoring Data From 640 Patients.Semantic proximity Read ↗

Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial.Semantic proximity Read ↗

Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?Semantic proximity Read ↗

Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation.Semantic proximity Read ↗

Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.Semantic proximity Read ↗

Paradoxical excitation on diphenhydramine may be associated with being a CYP2D6 ultrarapid metabolizer: three case reports.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.